UCB presented a comprehensive array of research from its epilepsy program at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, California. The presentations included clinical and real-world data, as well as medical research from across UCB’s pipeline programs, reinforcing the company's commitment to advancing care for individuals living with epilepsy and rare syndromes.
Fenfluramine Data Highlights
Sixteen abstracts focused on fenfluramine (Fintepla; UCB), with data covering real-world evidence, evaluations of populations with developmental and epileptic encephalopathies (DEEs), support from clinical trial data, and global and U.S. post-marketing safety data. These findings underscore the potential of fenfluramine for patients with rare and debilitating forms of epilepsy, such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Brad Chapman, head of U.S. Epilepsy and Rare Syndromes at UCB, noted the profound impact of fenfluramine on appropriate patients with DS and LGS, emphasizing that the data presented at AES reinforced this impact.
Addressing Unmet Needs for Women of Childbearing Age
UCB is actively addressing the unique needs of women of childbearing age with epilepsy through initiatives like the CONCEPTION project, funded by the Innovative Medicines Initiative. This project aims to reduce uncertainty about the effects of medications during pregnancy and breastfeeding, enabling women to make more informed treatment decisions. UCB is also partnering with the National Institutes of Health on the Task Force on Research Specific to Pregnant and Lactating Women, advising the Secretary of Health and Human Services on research gaps related to safe and effective therapies for these populations.
UCB's Broader Commitment to Epilepsy Care
UCB's commitment extends beyond specific treatments to encompass a broader understanding of the patient experience. The company leverages tools like social listening to better comprehend the experiences of individuals with epilepsy and rare syndromes, using this information to guide current and future decisions. With over 30 years of experience in the epilepsy space, UCB continues to explore new ways to improve care and support those impacted by these conditions.
Chapman highlighted the scientific innovation on display at AES, stating, "When I think about the 30-plus scientific abstracts presented, they truly reinforce our commitment to this community and to advancing science for patient care."
